机构:[a]Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经病学中心首都医科大学附属天坛医院[b]China National Clinical Research Center for Neurological Diseases, Beijing, China[c]Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经病学中心首都医科大学附属天坛医院[d]Department of Neurology, Tiantan Clinical Trial and Research Center for Stroke, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经病学中心首都医科大学附属天坛医院[e]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[f]Department of Neurosurgery, Changzhou No 1 People's Hospital, Changzhou, China[g]Department of Neurology, Tangshan Gongren Hospital, Tangshan, China[h]Department of Neurology, Chongqing Sanxia Central Hospital, Chongqing, China[i]Department of Neurology, Daping Hospital, Chongqing, China[j]Department of Neurology, Baotou Central Hospital, Baotou, China[k]Department of Neurology, Hubei Zhongshan Hospital, Wuhan, China[l]Department of Neurology, Liaocheng Third People's Hospital, Liaocheng, China[m]Department of Neurology, Luoyang Central Hospital affiliated to Zhengzhou University, China[n]Department of Neurology, People's Hospital of Linyi City, China[o]Department of Neurology, Tianjin TEDA Hospital, China[p]Department of Neurology, Chifeng Municipal Hospital, China[q]Department of Neurology, Fuzhou PLA General Hospital, China[r]Department of Neurology, Affiliated Hospital of Guiyang Medical College, China[s]Department of Neurology, Qilu Hospital of Shandong University, China[t]Department of Neurology, Yantai Hill Hospital, China[u]Department of Neurology, First Affiliated Hospital of Jinan University, China[v]Department of Neurology, Xinan Hospital, China[w]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China[x]Neuro-intensive Care Unit, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经病学中心首都医科大学附属天坛医院
Early recanalisation of the occluded cerebral vessel is the key to successful treatment of AIS.3 Before December 2014, the only proven and effective treatment for AIS was recombinant tissue-type plasminogen activator (alteplase).4 Intravenous recombinant tissue plasminogen activator (intravenous alteplase) given up to 3 hours of symptom onset is the only effective therapy for patients with AIS, this is supported by a National Institute of Neurological Disorders and Stroke (NINDS) study.5 Although the European Cooperative Acute Stroke Study III (ECASS III) study demonstrated benefit of alteplase in selected patients up to 4.5 hours after symptom onset, the use of intravenous alteplase is only approved for use within 3 hours, by the Chinese Food and Drug Administration (FDA), and the extended time window is seldom used in China. Owing to lack of public awareness of early stroke
第一作者机构:[a]Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
推荐引用方式(GB/T 7714):
Miao Z,Huo X,Gao F,et al.Endovascular therapy for Acute ischemic Stroke Trial (EAST): Study protocol for a prospective, multicentre control trial in China[J].Stroke and Vascular Neurology.2016,1(2):44-51.doi:10.1136/svn-2016-000022.
APA:
Miao, Z,Huo, X,Gao, F,Liao, X,Wang, C...&Wang, Y.(2016).Endovascular therapy for Acute ischemic Stroke Trial (EAST): Study protocol for a prospective, multicentre control trial in China.Stroke and Vascular Neurology,1,(2)
MLA:
Miao, Z,et al."Endovascular therapy for Acute ischemic Stroke Trial (EAST): Study protocol for a prospective, multicentre control trial in China".Stroke and Vascular Neurology 1..2(2016):44-51